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Rationale: There are several methods to measure cardiomyocyte and muscle contraction, but these require 
customized hardware, expensive apparatus, and advanced informatics or can only be used in single experimental 
models. Consequently, data and techniques have been difficult to reproduce across models and laboratories, 
analysis is time consuming, and only specialist researchers can quantify data.
Objective: Here, we describe and validate an automated, open-source software tool (MUSCLEMOTION) adaptable 
for use with standard laboratory and clinical imaging equipment that enables quantitative analysis of normal 
cardiac contraction, disease phenotypes, and pharmacological responses.
Methods and Results: MUSCLEMOTION allowed rapid and easy measurement of movement from high-
speed movies in (1) 1-dimensional in vitro models, such as isolated adult and human pluripotent stem cell-
derived cardiomyocytes; (2) 2-dimensional in vitro models, such as beating cardiomyocyte monolayers or small 
clusters of human pluripotent stem cell-derived cardiomyocytes; (3) 3-dimensional multicellular in vitro or in 
vivo contractile tissues, such as cardiac “organoids,” engineered heart tissues, and zebrafish and human hearts. 
MUSCLEMOTION was effective under different recording conditions (bright-field microscopy with simultaneous 
patch-clamp recording, phase contrast microscopy, and traction force microscopy). Outcomes were virtually 
identical to the current gold standards for contraction measurement, such as optical flow, post deflection, edge-
detection systems, or manual analyses. Finally, we used the algorithm to quantify contraction in in vitro and in 
vivo arrhythmia models and to measure pharmacological responses.
Conclusions: Using a single open-source method for processing video recordings, we obtained reliable 
pharmacological data and measures of cardiac disease phenotype in experimental cell, animal, and human 
models.  (Circ Res. 2018;122:e5-e16. DOI: 10.1161/CIRCRESAHA.117.312067.)
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The salient feature of cardiomyocytes is their ability to un-dergo cyclic contraction and relaxation—a feature critical 
for cardiac function. In many research laboratories and clinical 
settings it is, therefore, essential that cardiac contraction can be 
quantified at multiple levels, from single cells to multicellular or 
intact cardiac tissues. Measurement of contractility is relevant 
for analysis of disease phenotypes, cardiac safety pharmacology, 
and longitudinal measures of cardiac function over time, both 
in vitro and in vivo. In addition, human genotype–phenotype 
correlations, investigation of cardiac disease mechanisms, and 
the assessment of cardiotoxicity are increasingly performed on 
human-induced pluripotent stem cells (hiPSCs) derived from 
patients.1–3 Many of these studies are performed in nonspecialist 
laboratories, so that it is important that analysis methods are sim-
plified such that they can be used anywhere with access to just 
standard imaging equipment. Here, we describe a single method 
with high versatility that can be applied to most imaging outputs 
of cardiac contraction likely to be encountered in the laboratory 
or clinic.
In This Issue, see p 385 
Meet the First Author, see p 386
Electric and calcium signals are usually quantified in vitro 
using established technologies, such as patch-clamp electro-
physiology, multielectrode arrays (MEAs), cation-sensitive 
dyes, or cation-sensitive genetic reporters.4 Although experi-
mental details differ among laboratories, the values for these 
parameters are, with some approximations, comparable across 
laboratories, cardiomyocyte source, and cell culture configura-
tion (eg, single cells, multicellular 2-dimensional cardiomyocyte 
monolayers, and 3-dimensional [3D] cultures).5,6 However, there 
is no comparable method for measuring cardiac contraction 
across multiple platforms, despite this being a crucial functional 
parameter affected by many diseases or drugs.7 We have devel-
oped a method to address this that is built on existing algorithms 
and is fully automated but, most importantly, can be used on 
videos, image stacks, or image sequences loaded in the open-
source image-processing program ImageJ.8 Moreover, it is an 
open-source, dynamic platform that can be expanded, improved, 
and integrated for customized applications. The method, called 
MUSCLEMOTION, determines dynamic changes in pixel in-
tensity between image frames and expresses the output as a 
relative measure of movement during muscle contraction and 
relaxation. We applied the concept to a range of biomedical and 
pharmacologically relevant experimental models that included 
single human pluripotent stem cell-derived cardiomyocytes (hP-
SC-CMs), patterned or 2-dimensional cultures of hPSC-CMs, 
cardiac organoids, engineered heart tissues (EHTs), and isolated 
adult rabbit cardiomyocytes. Results were validated by compar-
ing outputs of the tool with those from 3 established methods 
for measuring contraction: optical flow, post deflection, and 
fractional shortening of sarcomere length. These methods have 
been tailored to (or only work on) specific cell configurations. 
Traction force microscopy, fractional shortening of sarcomere 
length, and microposts are predominantly suitable for single 
Nonstandard Abbreviations and Acronyms
3D 3-dimensional
Cas9 clustered regularly interspaced short palindromic repeat–
associated 9
EHT engineered heart tissue
hiPSC human induced pluripotent stem cell
hiPSC-CM human induced pluripotent stem cell-derived cardiomyocyte
hPSC human pluripotent stem cell
hPSC-CM human pluripotent stem cell-derived cardiomyocyte
MEA multielectrode array
MHC myosin heavy chain
MYH7 myosin heavy chain, isoform 7
Novelty and Significance
What Is Known?
• Quantification of cardiac contraction in vitro and in vivo is essential 
to characterize effects of drugs and disease on cardiac myocyte and 
heart function.
• Most current software tools to measure and quantify contraction re-
quire tailored hardware, expensive software licences, arbitrary analy-
sis thresholds, or advanced informatics skills not available in many 
laboratories.
• Validation of data and reproducibility across different laboratories, plat-
forms, or cell configurations is limited because complex data analysis 
methodologies are not directly comparable.
What New Information Does This Article Contribute?
• MUSCLEMOTION is an open-source, simple software tool created and 
validated with current gold standards for measurement across differ-
ent laboratories to analyze contraction of cardiac myocytes and hearts 
from high-speed movies.
• MUSCLEMOTION can measure and quantify contraction from multiple 
recording conditions, cell configurations, and genotypes in vitro and 
in vivo. Absolute force values or displacement values can be obtained 
on calibration.
• MUSCLEMOTION code is freely available and can be easily implement-
ed by scientists and clinicians in basic and applied research.
Contractile function of the heart is often impaired in cardiac disease 
and in response to drugs, where there may be alterations in the 
force, duration, and amplitude of contraction. In this study, cardiac 
research scientists and clinicians pooled expertise to create and val-
idate a new software tool, called MUSCLEMOTION, which serves as 
a flexible platform for quantification of cardiac contraction in many 
commonly used recording conditions or cell configurations; impor-
tantly, MUSCLEMOTION is open source and shared here to promote 
data reproducibility, data comparison, and offer others in the field a 
reliable and robust starting point to which tailored applications may 
be developed. MUSCLEMOTION can be used effectively to validate 
the functional consequences of disease on cell contraction, to quan-
tify and compare relative or absolute parameters in different culture 
conditions, drug responses, or even to characterize in vivo disease 
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Figure 1. Algorithm construction and validation. A, Principle of pixel intensity difference by subtraction of imgref of imgi, and 
measurement of the nonzero area after image subtraction. B, Principle of using pixel intensity difference as a measure of displacement 
and as a measure of displacement velocity. C, Schematic overview of MUSCLEMOTION. Green blocks indicate basic steps of the 
algorithm. Dark green blocks indicate important user input choices. Plots within light green blocks indicate results. Optional steps are 
shown in blue blocks, with graphical representation of the analyzed parameters indicated by red lines. Three result files are generated 
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cells.8,9 Cardiomyocyte edge or perimeter detection is suitable 
for adult cardiomyocytes but challenging for immature hPSC-
CMs because of poorly defined plasma membrane borders and 
concentric contraction,10 whereas large post deflection is suitable 
for EHTs or small cardiac bundles11 but less so for single cells. 
Our MUSCLEMOTION software by contrast can be used for all 
of these applications without significant adaptions. Furthermore, 
it can be used for multiparameter recording conditions and ex-
perimental settings using transmitted light microscopy, fluores-
cent membrane labeling, fluorescent beads embedded in soft 
substrates, or patch-clamp video recordings. Drug responses 
to positive and negative inotropic agents were evaluated across 
4 different laboratories in multiple cell configurations using 
MUSCLEMOTION with reliable predictions of drug effects 
from all laboratories. Furthermore, MUSCLEMOTION was 
also applicable to optical recordings of zebrafish hearts in vivo, 
where it represented a significant time saving in analysis and 
in human echocardiograms. This versatile tool thus provides a 
rapid and straightforward way to detect disease phenotypes and 
pharmacological responses in vitro and in vivo.
Methods
Extended methods are in the Online Data Supplement.
The datasets generated and analyzed during the current study are 
available from the corresponding authors on reasonable request.
Code Availability
MUSCLEMOTION source code has been written in the ImageJ 
Macro Language and is included in the Online Dataset and is avail-
able for use and further development.
Model Cell
The in silico cardiomyocyte-like model (Figure 1D, 1F, and 1G) was 
created using Blender v2.77.
Optical Flow Analysis
Optical flow analysis was implemented in LabVIEW as described by 
Hayakawa et al.12,13
Generation of hiPSC-Hypertrophic 
Cardiomyopathy Isogenic Triplet Using  
CRISPR/Cas9
Dual guide RNA/Cas9 (clustered regularly interspaced short palindromic 
repeat–associated 9)-Nickase strategy was designed to introduce the 
MYH7 (myosin heavy chain, isoform 7)-C9123T SNP (single-nucle-
otide polymorphism; encoding the R453C-β-MHC [myosin heavy 
chain] modification) in ReBl-PAT hiPSC line, as described previously.14
hPSC Culture and Differentiation
hPSCs from multiple independent cell lines (Online Table I) were dif-
ferentiated to cardiomyocytes as described previously15–18 or with the 
Pluricyte Cardiomyocyte Differentiation Kit (Pluriomics B.V.) accord-
ing to the manufacturer’s protocol. Experiments were performed at 18 
to 30 days after initiation of differentiation, depending on the cell source 
and configuration. Pluricytes were kindly provided by Pluriomics B.V.
Patch-Clamp Recordings on hPSC-CMs
Electrophysiological recordings of isolated hPSC-CMs were per-
formed as described previously.17
MEA Recordings of hPSC-CMs
Field potentials from MEAs were recorded and analyzed as published 
previously.19
Movement of Embedded Beads
Gelatin-patterned polyacrylamide gels containing fluorescent beads 
were generated and analyzed as described previously.20
Monolayers of hPSC-CMs
Twenty-five thousand to 40 thousand cells were plated per Matrigel-
coated glass ø10 mm coverslip.
Cardiac Organoids
Cardiac organoids composed of hPSC-CMs and hPSC-derived endo-
thelial cells were generated as described previously.18
Adult Cardiomyocytes
Cardiomyocytes were isolated from New Zealand white male rabbits 
as described previously.21
Membrane Labeling
hPSC-CMs were plated on Matrigel-coated glass-bottom 24-well 
plates and labeled with CellMask Deep Red according to the manu-
facturer’s instructions.
Engineered Heart Tissues
EHTs were generated and analyzed as described previously.15
Zebrafish Hearts
Zebrafish hearts were recorded, treated, and analyzed as described 
previously.22
Echocardiograms
Anonymized ultrasounds of 5 adult patients were selected from the 
echocardiography database of the Leiden University Medical Center.
Statistics
One-way ANOVA for paired or unpaired measurements was applied to 
test the differences in means on normalized drug effects. P values ob-
tained from 2-tailed pairwise comparisons were corrected for multiple 
testing using Bonferroni method. Statistical analyses were performed 
with R v3.3.3. P values <0.05 were considered statistically significant 
and indicated with an asterisk (*). N values represent biological repeats.
Results
Algorithm Development
The principle underlying the algorithm of MUSCLEMOTION 
is the assessment of contraction using an intuitive approach 
quantifying absolute changes in pixel intensity between a refer-
ence frame and the frame of interest, which can be described as
where imgi  is the frame of interest, imgref  is the reference 
frame, and imgresult  is the resulting image. For every pixel in 
the frame, each reference pixel is subtracted from the cor-
responding pixel of interest, and the difference is presented 
in absolute numbers. Unchanged pixels result in low (black) 
values, whereas pixels that are highly changed result in high 
img img imgi ref result− =
Figure 1 Continued. relevant traces and a log file are generated and saved (not shown in schematic). D, Schematic of the contractile 
pattern of the artificial cell and relative parameters corresponding to amplitude of contraction (A), time-to-peak (t1), and relaxation time 
(t2). E, Correlation between input (x axis) and output (y axis) parameters used to validate MUSCLEMOTION with 2 artificial cells. F and G, 
Frame representing the 2 artificial cells built for MUSCLEMOTION validation and their relative output parameters. SNR indicates signal-to-
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(white) values (Figure 1A). Next, the mean pixel intensity of 
the resulting image is measured. This is a quantitative mea-
sure of how much the pixels have moved compared with the 
reference frame: more white pixels indicate more changing 
pixels and, thus, more displacement. When a series of images 
is analyzed relative to the same reference image, the output 
describes the accumulated displacement over time (measure 
of displacement; Figure 1B).
However, if a series of images is analyzed with a reference 
frame that depends on the frame of interest (eg, img imgref i= −1 ), 
this results in a measure of the relative displacement per in-
terframe interval. We defined this parameter as contraction 
velocity (measure of velocity; Figure 1B).
Because velocity is the first derivative of displacement 
in time, the first derivative of the measure of displacement 
should resemble the measure of velocity derived from im-
age calculations. To test the linearity of the method, 3 movies 
of moving blocks were analyzed. The block moved back and 
forth at 2 different speeds in each direction (where v v2 12= ⋅ ): 
(1) along the x axis, (2) along the y axis, and (3) along both axes 
(Online Movie I). As expected, the measure of displacement and 
velocity showed a linear correlation (Online Figure I). This does 
not hold when the position of the block in imgi  does not overlap 
the position of the block in imgref , with a consequent satura-
tion in the measure of displacement (ie, max pixel white value; 
Online Figure II). Therefore, comparison of the differentially de-
rived velocities should approximately overlap in the absence 
of pixel saturation. This was used as a qualitative parameter to 
determine whether the algorithm outputs were reliable.
Figure 2. Correlation of results with gold standards. A, Bright-field image of isolated human pluripotent stem cell-derived 
cardiomyocytes (hPSC-CMs; Ai), with maximum projection step visually enhanced with a fire Look Up Table (Aii); contraction (Aiii) and 
velocity (Aiv) profiles of each individual beat have been generated by MUSCLEMOTION and temporally aligned; linear regression analysis 
between MUSCLEMOTION results (x axis) and optical flow results (y axis; Av). B, Phase contrast image of hPSC-CM monolayers (Bi), 
with maximum projection step visually enhanced with a fire Look Up Table (Bii); contraction (Biii) and velocity (Biv) profiles of each 
individual beat have been generated by MUSCLEMOTION and temporally aligned; linear regression analysis between MUSCLEMOTION 
results (x axis) and those obtained with optical flow results (y axis; Bv). C, Phase contrast image of cardiac organoids (Ci), with maximum 
projection step visually enhanced with a fire Look Up Table (Cii); contraction (Ciii) and velocity (Civ) profiles of each individual beat 
have been generated by MUSCLEMOTION and temporally aligned; linear regression analysis between MUSCLEMOTION results (x axis) 
and those obtained with optical flow results (y axis; Cv). D, Live view of an engineered heart tissue (EHT) during contraction analysis. 
Scale bar, 1 mm. Di, with maximum projection step visually enhanced with a fire Look Up Table (Dii); contraction (Diii) and velocity (Div) 
profiles of each individual beat have been generated by MUSCLEMOTION and temporally aligned; linear regression analysis between 
MUSCLEMOTION results (x axis) and those obtained with post deflection (y axis; Dv). E, Bright-field image of adult rabbit cardiomyocytes 
(Ei), with maximum projection step visually enhanced with a fire Look Up Table (Eii); contraction (Eiii) and velocity (Eiv) profiles of each 
individual beat have been generated by MUSCLEMOTION and temporally aligned; linear regression analysis between MUSCLEMOTION 
results (x axis) and those obtained from sarcomere fractional shortening calculation with Fast Fourier Transform (y axis; Ev). For details on 
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Algorithm Implementation
MUSCLEMOTION was then modified to handle typical ex-
perimental recordings by (1) improving the signal-to-noise 
ratio, (2) automating reference frame selection, and (3) pro-
gramming built-in checks to validate the generated output 
data (Figure 1C). The signal-to-noise ratio was increased by 
isolating the pixels of interest in a 3-step process: (1) maxi-
mum projection of pixel intensity in the complete contraction 
stack, (2) creation of a binary image of this maximum projec-
tion with a threshold level equal to the mean grey value plus 
SD, and (3) multiplication of the pixel values in this image by 
the original contraction and speed of the contraction image 
stack (Online Figure III). This process allowed the algorithm 
to work on a region of interest with movement above the noise 
level only.
Next, a method was developed to identify the correct 
imgref  from the speed of contraction image stack by compar-
ing values obtained from the frame-to-frame calculation with 
their direct neighboring values, while also checking for the 
lowest absolute value (Online Figure IV).
The reliability of MUSCLEMOTION for structures with 
complex movements was validated using a custom-made con-
tracting 3D “synthetic cardiomyocyte” model (Figure 1D, 
1F, and 1G) that was adapted to produce contractions with 
known amplitude and duration. Linearity was preserved dur-
ing the analysis of the contraction and velocity; other output 
parameters of the analysis matched the input parameters 
(Figure 1E). A second 3D model (Figure 1G), with a repeti-
tive pattern aimed to create out-of-bounds problems, was also 
generated. As expected, contraction amplitude information 
here was not linear (Figure 1E), although contraction veloc-
ity and temporal parameters did remain linear (Figure 1E and 
1G). To mitigate this problem, we implemented an option for a 
10σ Gaussian blur filter that can be applied on demand to bio-
logical samples that presented highly repetitive patterns (eg, 
sarcomeres in adult cardiomyocytes).
Algorithm Application to Multiple Cell 
Configurations and Correlation With Existing Gold 
Standards
This set of experiments aimed to investigate the versatility of 
MUSCLEMOTION and examine how its performance com-
pared with standard measures used in each system: (1) optical 
flow for isolated hPSC-CMs, monolayers, and organoids; (2) 
post deflection for EHT; and (3) sarcomere length fractional 
shortening for adult cardiomyocytes. Remarkably, standard 
methods currently used measure only contraction or contrac-
tion velocity. Linearity was preserved in all cases during the 
analyses, demonstrating the reliability of the results (Online 
Figure V).
First, single hPSC-CMs (Figure 2A; Online Movie II) 
exhibited concentric contraction (Figure 2Aii), and contrac-
tion velocity amplitudes correlated well with the amplitudes 
Figure 3. Application of 
MUSCLEMOTION to multiple biological 
situations. Representative examples 
with enhancement of moving pixels (top) 
and profiles (bottom) of contraction 
(A through D, red), velocity (A through 
D, black), and voltage (A and C, blue), 
respectively, obtained from high-speed 
movies of patched human pluripotent 
stem cell-derived cardiomyocytes 
(hPSC-CMs; A), aligned hPSC-CMs on 
polyacrylamide gels with fluorescent 
beads (B), monolayers of human-induced 
pluripotent stem cell CMs seeded on 
multielectrode arrays (C), and hPSC-CMs 
whose membranes have been labeled 
with CellMask Deep Red (D). For details 
on cell sources and cell lines, please refer 
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Figure 4. Pharmacological challenge with positive and negative inotropic compounds. A, Average dose–response curves (black 
traces) and single measurements for several parameters obtained in isolated, spontaneously beating, aligned human pluripotent stem 
cell-derived cardiomyocytes (hPSC-CMs) treated with isoprenaline (left, red) and nifedipine (right, green). B, Average dose–response 
curves (black traces) and single measurements for several parameters obtained from monolayers of hPSC-CMs treated with isoprenaline 
(left, red) and nifedipine (right, green). C, Average dose–response curves (black traces) and single measurements for several parameters 
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obtained by optical flow analysis (R2=0.916; Figure 2Av). In 
contrast to single cells, the area of contraction for hPSC-CM 
monolayers was distributed heterogeneously throughout the 
whole field (Figure 2Bii; Online Movie III). Optical flow anal-
ysis was compared with our measure of velocity (Figure 2Biv); 
this showed a good linear correlation (R2=0.803; Figure 2Bv). 
Complex (mixed and multicellular) 3D configurations were 
also investigated by analyzing hPSC-derived cardiac or-
ganoids18 (Online Movie IV) and EHTs15 (Online Movie 
V). Cardiac organoids showed moderate levels of contrac-
tion throughout the tissue (Figure 2Cii), whereas the EHTs 
showed high deflection throughout the bundle (Figure 2Dii). 
The contraction velocity of the organoids correlated well with 
the output of optical flow analysis (R2=0.747; Figure 2Cv). 
Similarly, contraction amplitudes in EHTs showed high linear 
correlation (R2=0.879) with the absolute force values derived 
from measurement of pole deflection (Figure 2Dv). Finally, 
single adult rabbit ventricular cardiomyocytes were analyzed 
(Figure 2E; Online Movie VI). Large movement was evident 
around the long edges of the cardiomyocyte (Figure 2Eii). 
These cells were analyzed with a 10σ Gaussian blur fil-
ter, which also minimized (unwanted) effects of transverse 
movements on contraction patterns. Linearity was preserved 
(Online Figure V), despite the repetitive pattern of the sarco-
meres, and this resulted in accurate measures of both contrac-
tion (Figure 2Eiii) and speed of contraction (Figure 2Eiv). 
The contraction amplitude of the adult cardiomyocytes stimu-
lated at 1 Hz correlated well with the output of sarcomeric 
shortening using fast Fourier transform analysis23 (R2=0.871; 
Figure 2Ev). Thus, the MUSCLEMOTION algorithm yielded 
data in these initial studies comparable with methods of analy-
sis tailored for the individual platforms.
Application of MUSCLEMOTION to Multiple 
Imaging and Recording Platforms
To examine whether MUSCLEMOTION could potentially 
be used in applications that measure other aspects of cardio-
myocyte functionality in parallel, we first determined the elec-
trophysiological properties of hPSC-CMs using patch clamp 
while recording their contractile properties through video im-
aging. This allowed simultaneous quantitative measurement 
of action potentials and contraction (Figure 3A), for in-depth 
investigation of their interdependence. We observed a typical24 
profile of action potential followed by its delayed contraction.
To measure contractile force in combination with con-
tractile velocity in single cardiomyocytes, we integrated fluo-
rescent beads into polyacrylamide substrates patterned with 
gelatin (Figure 3B), where the displacement of the beads is a 
measure of cardiomyocyte contractile force20 (Online Movie 
VII). Additionally, field potentials and contraction profiles 
of hPSC-CMs were analyzed from simultaneous electric and 
video recordings of monolayers plated on MEAs (Figure 3C; 
Online Movie VIII).
Similarly, effective quantification of contraction profiles 
was obtained for fluorescently labeled hPSC-CM mono-
layer cultures (Figure 3D; Online Movie IX), allowing 
MUSCLEMOTION to be integrated on high-speed fluores-
cent microscope systems for automated data analysis.
Application of MUSCLEMOTION to Drug 
Responses in Different Cell Models in Different 
Laboratories
Having shown that MUSCLEMOTION was fit-for-purpose 
in analyzing contraction over a variety of platforms, we next 
sought to demonstrate its ability to detect the effects of posi-
tive and negative inotropes. This is essential for ensuring the 
scalability of the tool over multiple platforms, particularly in 
the context of hiPSC-CMs where regulatory authorities and 
pharmaceutical companies are interested in using these cells 
as human heart models for drug discovery, target validation, 
or safety pharmacology.25 For isoprenaline and nifedipine, the 
main parameters of interest are contraction amplitude (iso-
prenaline and nifedipine), relaxation time (isoprenaline), and 
contraction duration (nifedipine).
The relaxation time of spontaneously beating isolated 
hPSC-CMs on gelatin-patterned polyacrylamide substrates 
treated with isoprenaline significantly decreased as expected 
at doses >1 nmol/L. Similar to what has been reported,26 con-
traction amplitude decreased at doses >1 nmol/L. Nifedipine 
treatment decreased both contraction amplitude and dura-
tion starting from 3 nmol/L, respectively (Figure 4A). In 
paced (1.5 Hz) hPSC-CM monolayers, no significant effects 
were measured after addition of isoprenaline on either re-
laxation time or contraction amplitude. Nifedipine caused a 
Figure 4 Continued. curves (black traces) and single measurements for several parameters obtained in engineered heart tissues treated 
with isoprenaline (left, red) and nifedipine (right, green). E, Average dose–response curves (black traces) and single measurements for 
several parameters obtained in adult rabbit cardiomyocytes treated with isoprenaline (left, red) and verapamil (right, green). Average data 
points (black) represent mean±standard error of the mean. For details on cell sources and cell lines, please refer to Online Table I. Data 
information: P values DMSO (dimethyl sulfoxide) vs dose. Ai, 0.3 nmol/L, 0.2897; 1 nmol/L, 3.4/106; 3 nmol/L, 3.8/108; 10 nmol/L, 7/1011; 30 
nmol/L, 7.3/1010; and 100 nmol/L, 2.4/1010. Aii, 0.3 nmol/L, 1; 1 nmol/L, 0.0645; 3 nmol/L, 0.0136; 10 nmol/L, 8.2/105; 30 nmol/L, 0.0063; 
and 100 nmol/L, 2.4/106. N=14; 14; 14; 14; 14; 14; 14. Aiii, 3 nmol/L, 0.6533; 10 nmol/L, 4/105; 30 nmol/L, 2/109; and 100 nmol/L, 1.5/1015. 
Aiv, 3 nmol/L, 0.00 054; 10 nmol/L, 1.9/1011; 30 nmol/L, <2/1016; and 100 nmol/L, <2/1016. N=14; 14; 14; 14; 14. P values baseline vs dose. 
Bi, 1 nmol/L, 1; 3 nmol/L, 1; 10 nmol/L, 1; 30 nmol/L, 1; 100 nmol/L, 1; and 300 nmol/L, 1. Bii, 1 nmol/L, 1; 3 nmol/L, 1; 10 nmol/L, 1; 30 
nmol/L, 1; 100 nmol/L, 1; and 300 nmol/L, 1. N=6; 5; 6; 6; 6; 6; 6. Biii, 3 nmol/L, 1; 10 nmol/L, 1; 30 nmol/L, 1; 100 nmol/L, 0.00 801; 300 
nmol/L, 2.7/109; and 1000 nmol/L, 1.8/1010. Biv, 3 nmol/L, 1; 10 nmol/L, 1; 30 nmol/L, 1; 100 nmol/L, 0.00 084; 300 nmol/L, 2.9/1011; and 
1000 nmol/L, 1.5/1011. N=6; 6; 6; 6; 6; 6; 6. P values baseline vs dose. Ci, 1 nmol/L, 1; 3 nmol/L, 1; 10 nmol/L, 1; 30 nmol/L, 1; 100 nmol/L, 
1; and 300 nmol/L, 1. Cii, 1 nmol/L, 1; 3 nmol/L, 1; 10 nmol/L, 1; 30 nmol/L, 1; 100 nmol/L, 1; and 300 nmol/L, 1. N=5; 5; 4; 5; 4; 4; 4. Ciii, 
3 nmol/L, 1; 10 nmol/L, 1; 30 nmol/L, 1; 100 nmol/L, 0.00 181; 300 nmol/L, 2.9/106; and 1000 nmol/L, 1.7/105. Civ, 3 nmol/L, 1; 10 nmol/L, 
1; 30 nmol/L, 1; 100 nmol/L, 0.54 836; 300 nmol/L, 0.01 392; and 1000 nmol/L, 8.2/105. N=5; 5; 4; 5; 5; 5; 3. P values baseline vs dose. Di, 
1 nmol/L, 1; 3 nmol/L, 1; 10 nmol/L, 1; 30 nmol/L, 0.47; and 100 nmol/L, 1. Dii, 1 nmol/L, 0.02 318; 3 nmol/L, 0.00 170; 10 nmol/L, 0.00 028; 
30 nmol/L, 0.00 044; and 100 nmol/L, 0.00 113. N=5; 5; 5; 5; 5; 5. Diii, 3 nmol/L, 1; 10 nmol/L, 1; 30 nmol/L, 1; and 100 nmol/L, 3/105. Div, 
3 nmol/L, 1; 10 nmol/L, 0.49 856; 30 nmol/L, 0.01 473; and 100 nmol/L, 7/106. N=6; 6; 6; 6; 6. P values Krebs vs dose. Ei, 1 nmol/L, 1; 3 
nmol/L, 1. Eii, 1 nmol/L, 1; and 3 nmol/L, 0.54. N=6; 10; 7. P values DMSO vs dose. Eiii, 10 nmol/L, 1; 30 nmol/L, 1; 100 nmol/L, 1; and 
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progressive decrease in contraction duration and amplitude 
in a concentration-dependent manner starting at 100 nmol/L 
(Figure 4B). Similarly, cardiac organoids paced at 1.5 Hz 
showed no significant effects on both relaxation time and con-
traction amplitude with isoprenaline, whereas both parameters 
decreased after nifedipine, starting from 100 and 300 nmol/L, 
respectively (Figure 4C). EHTs paced at 1.5× baseline fre-
quency and analyzed with MUSCLEMOTION showed a posi-
tive inotropic effect starting from 1 nmol/L isoprenaline and 
a negative inotropic effect starting at 30 nmol/L nifedipine as 
reported previously15 (Figure 4D).
Paced (1 Hz) adult rabbit cardiomyocytes exhibited no 
significant increase in relaxation time and contraction am-
plitude at any isoprenaline concentration. At concentrations 
>3 nmol/L, adult cardiomyocytes exhibited after-contractions 
and triggered activity during diastole, which hampered their 
ability to be paced at a fixed frequency. No significant effects 
were observed on contraction duration with nifedipine, where-
as contraction amplitude significantly decreased in a dose-de-
pendent manner starting from 100 nmol/L (Figure 4E). Data 
generated by post deflection and sarcomere fractional shorten-
ing are available for comparison purposes in Online Figure VI.
Analysis of Disease Phenotypes In Vitro
Contractility of hiPSC-CMs carrying mutations associated 
with long-QT syndrome type 127 and hypertrophic cardio-
myopathy were characterized in distinct cell configurations: 
monolayers plated on MEAs and EHTs, respectively. As dem-
onstrated previously, long-QT syndrome type 1 phenotype 
was captured as a prolongation of the QT interval of the field 
potential.17,27 As expected, contraction duration measured with 
MUSCLEMOTION was also prolonged (Figure 5A and 5B). 
EHTs were fabricated from an isogenic triplet carrying the 
MYH7R453C mutation either in homozygosity or heterozygosity 
and showed a gene dosage effect on the contractility recapitu-
lating disease severity.
Analysis of Disease Phenotypes In Vivo
To extend analysis to hearts in vivo, we took advantage of the 
transparency of zebrafish, which allows recording of contract-
ing cardiac tissue in vivo (Figure 6A; Online Movie X). It 
was previously shown that mutations in GNB5 are associated 
with a multisystem syndrome in human, with severe brady-
cardia at rest. Zebrafish with loss-of-function mutations in 
gnb5a and gnb5b were generated. Consistent with the syn-
drome manifestation in patients, zebrafish gnb5a/gnb5b dou-
ble mutant embryos showed severe bradycardia in response to 
parasympathetic activation.22 Irregularities in heart rate were 
visually evident and were clearly distinguishable from the 
wild-type counterpart after analysis with MUSCLEMOTION 
(Figure 6B). Quantification of the heart rate of these zebrafish-
es with MUSCLEMOTION highly correlated (R2=0.98) with 
the results of the published manual analyses22 (Figure 6C). 
There was, however, a striking time saving for operators in 
performing the analysis using the algorithm (5–10× faster 
than manual analysis; 150 recordings were analyzed in 5 
hours versus 4 days) without compromising the accuracy of 
the outcome. Qualitative analysis of contraction patterns al-
lowed rapid discrimination between arrhythmic versus nonar-
rhythmic responses to carbachol treatment (Figure 6C).
Finally, we examined human echocardiograms from 5 
healthy and cardiomyopathic individuals (Figure 6D; Online 
Movie XI). To assess ventricular function, videos were 
cropped to exclude movement contributions of the atria and 
valves. MUSCLEMOTION enabled rapid quantification of 
temporal parameters from standard ultrasound echography 
(Figure 6E), such as time-to-peak, relaxation time, R-R inter-
val, and the contraction duration (Figure 6F).
Figure 5. In vitro disease phenotypes. A, Field potential and contraction profile of wild-type (black) and long-QT syndrome type 1 
(LQT1; gray) human pluripotent stem cell-derived cardiomyocyte monolayers on multielectrode arrays. B, Quantitative analysis of the 
QT interval and the contraction duration. C, Raw (top) and normalized (bottom) contraction profiles of hypertrophic cardiomyopathy–
engineered heart tissues from MYH7 (myosin heavy chain, isoform 7)wt/wt (solid), MYH7wt/mut (dashed), and MYH7mut/mut (dotted) cell lines. D, 
Quantitative analysis of contraction amplitude and contraction duration. Data information: P values QT interval: wild type (WT) vs LQT1, 
0.012. P values contraction duration: WT vs LQT1, 0.012. P values contraction amplitude: MYH7wt/wt vs MYH7wt/mut, 0.026; MYH7wt/wt vs 
MYH7mut/mut, 6/106; and MYH7wt/mut vs MYH7mut/mut, 0.00 065. P values contraction duration: MYH7wt/wt vs MYH7wt/mut, 0.062; MYH7wt/wt vs 
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Discussion
A reliable and easy-to-use method to quantify cardiac mus-
cle contraction would be of significant benefit to many basic 
and clinical science laboratories to characterize cardiac dis-
ease phenotypes, understand underlying disease mechanisms, 
and predict cardiotoxic effects of drugs.15,26 Quantification of 
frame-to-frame differences in pixel intensity has been used in 
recent reports with success10; however, the full spectrum of 
applications for which these algorithms are relevant, how their 
output data correlate with gold standards in each system, and 
software performance, specifications, license, and software 
availability, have remained unclear.
Here, we developed and tested a user-friendly, inexpen-
sive, open-source software platform that serves this purpose 
in a variety of biological systems of heart tissue. Its integra-
tion into current research practices would benefit data sharing, 
reproducibility, comparison, and translation in many clinically 
relevant contexts.28
The linearity and reliability of MUSCLEMOTION were 
validated using a 3D reconstructed artificial cardiomyocyte, 
which gave the expected linear correlations between known 
inputs and the outputs (Figure 1D through 1F). When random 
repetitive patterns were applied, amplitude outputs differed 
from inputs, suggesting a potential limitation to measuring 
contraction amplitudes in highly repetitive biological samples 
(such as when sarcomere patterns are well organized), whereas 
temporal parameters remained valid (Figure 1D, 1E, and 1G). 
However, conditions such as these would be unlikely in stan-
dard biological samples, where camera noise significantly 
reduces the possibility of saturating pixel movement. We par-
tially attenuated this problem by applying, on user demand, a 
10σ Gaussian blur filter, which significantly increased the ac-
curacy of MUSCLEMOTION with highly repetitive structures. 
Also, to increase reliability, we built in additional controls to 
detect any mismatches and errors. MUSCLEMOTION can au-
tomatically identify and select the reference frame and increase 
the signal-to-noise ratio—features which were particularly rel-
evant in reducing user bias and interaction while improving 
user experience. MUSCLEMOTION is valid in a wide range 
of illumination conditions without changing temporal param-
eters; however, exposure time was linearly correlated with con-
traction amplitude (Online Figure VII). Furthermore, a series 
of conditions in which there is no contraction has been used 
as a negative control (Online Figure VIII). Batch mode analy-
ses and data storage in custom folders were also incorporated 
to support overnight automated analyses. For accurate quan-
tification of amplitude, time-to-peak, and relaxation time, an 
appropriate sampling rate should be chosen. For applications 
Figure 6. In vivo disease phenotypes. A, Representative examples of wild-type (top) and gnb5a/gnb5b mutant (bottom) zebrafish 
and relative enhancement of moving pixels. B, Representative qualitative analyses of normal (top) and arrhythmic (bottom) contraction 
profiles from wild-type and gnb5a/gnb5b mutant zebrafish treated with carbachol. C, Correlation of results obtained from manual (x axis) 
vs automatic (y axis) detection of beating frequency (top); distribution of normal (green) and arrhythmic (red) contraction patterns in 
baseline condition (B) and after treatment with carbachol (C) in wild-type and gnb5a/gnb5b mutant zebrafish (bottom). D, Representative 
echocardiograms of healthy (top) and cardiomyopathic (bottom) human individuals. Ventricles have been manually cropped, and the 
enhancement of moving pixels is overlaid. E, Representative qualitative analyses of normal (top) and poor (bottom) ventricular functions. 
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similar to those described here, we recommend recording rates 
>70 frames per second to sample correctly the fast upstroke of 
the time-to-peak typical of cardiac tissue. This recording rate 
is easily achievable even using smartphone slow-motion video 
options (≈120/240 frames per second), obviating the need for 
dedicated cameras and recording equipment if necessary.
We demonstrated excellent linear correlations between our 
software tool and multiple other standard methods independent 
of substrate, cell configuration, and technology platform and 
showed that MUSCLEMOTION is able to capture contraction 
in a wide range of in vivo and in vitro applications (Figures 2 
and 3). Specifically, we identified several advantages compared 
with optical flow algorithms in terms of speed and the absence 
of arbitrary binning factors or thresholds, which, when modi-
fied, profoundly affect the results. One limitation compared 
with optical flow or EHT standard algorithm is that the tool 
lacks qualitative vector orientation, making it more difficult 
to assess contraction direction. Particularly important was the 
correlation with force data calculated from the displacement of 
flexible posts by EHTs. This indicates that when the mechani-
cal properties of substrates are known,29 MUSCLEMOTION 
allows absolute quantification of contractile force. Technical 
limitations of the EHT recording system allowed us to analyze 
only movies with JPEG (Joint Photographic Experts Group) 
compression; this resulted in loss of pixel information that might 
have negatively influenced the correlation shown. For better and 
more accurate results on contraction quantification, nonlossy/
uncompressed video formats should be used for recordings be-
cause individual pixel information is lost on compression and, 
therefore, not available for analysis by MUSCLEMOTION.
We proposed and validated practical application in phar-
macological challenges using multiple biological preparations 
recorded in different laboratories; this means that immediate 
use in multiple independent high-throughput drug-screening 
pipelines is possible without further software development be-
ing required, as recently applied for a drug-screening protocol 
on cardiac organoids from hPSCs.18 Intuitively, the possibil-
ity of having interassay comparisons will also be of particular 
relevance where comparisons of contraction data across mul-
tiple platforms are required by regulatory agencies or consor-
tia (eg, CiPA [Comprehensive In Vitro Proarrhythmia Assay] 
and CSAHi [Consortium for Safety Assessment Using Human 
iPS Cells]).5,6,25,30 Moreover, this might offer a quantitative ap-
proach to investigate how genetic or acquired diseases of the 
heart (eg, cardiomyopathies7 and long-QT syndrome31), heart 
failure resulting from anticancer treatments,32,33 or maturation 
strategies20,34,35 affect cardiac contraction. The possibility of 
linking in vitro with in vivo assays, with low-cost technologies 
applicable with existing hardware, certainly represents an ad-
vantage as demonstrated by automatic quantification of zebraf-
ish heartbeats and human echocardiograms (Figure 6). Overall, 
these results clearly demonstrated that contraction profiles 
could be derived and quantified in a wide variety of commonly 
used experimental and clinical settings. MUSCLEMOTION 
might represent a starting point for a swift screening method 
to provide clinically relevant insights into regions of limited 
contractility in the hearts of patients. We encourage further de-
velopment of this open-source platform to fit specific needs; 
future areas of application could include skeletal or smooth 
muscle in the same range of formats described here.
MUSCLEMOTION allows the use of a single, transparent 
method of analysis of cardiac contraction in many modalities 
for rapid and reliable identification of disease phenotypes, 
potential cardiotoxic effects in drug-screening pipelines, and 
translational comparison of contractile behavior.
Limitations
Saturation of pixel movements may affect contraction ampli-
tudes. However, as demonstrated with the artificial cardio-
myocyte, contraction velocity and all temporal parameters 
remained valid. We also minimized the impact of highly re-
petitive structures on the output of MUSCLEMOTION by 
applying a Gaussian filter, which also helped in reducing 
the impact of transverse movements on contraction profiles. 
High-frequency contraction might complicate baseline detec-
tion, especially if the duration of the contracted state is similar 
to that of the relaxed (eg, approaching sinusoidal). We have 
implemented a fast mode option that captures reliable base-
line values even at high contraction rates. MUSCLEMOTION 
does not measure absolute values of cell shortening or force 
of contraction. However, as demonstrated by correlations with 
these physical quantities (Figure 2D and 2Ev), specific setups 
can be calibrated to obtain such readout.
Adult cardiomyocytes contract dominantly along the lon-
gitudinal axis. However, hPSC-CMs are highly variable in 
shape, often showing concentric contractions, so that effects 
of transverse movement are usually intrinsic to the experimen-
tal model and they should be considered in the global contrac-
tion analysis. Indirect transverse movements originating from 
uncontrolled experimental conditions or moving objects other 
than those of interest (eg, vibrations, sample shift, floating de-
bris, and air bubbles) should be avoided because they might 
lead to overestimation of the cardiomyocyte contraction.
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